ClinicalTrials.gg
Status unknownNCT04678908Updated Jun 1, 2022

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HB0025 in Tumor, Subjects, sponsored by Huabo Biopharm Co., Ltd.. Status unknown at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Huabo Biopharm Co., Ltd. · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, dose escalation and expansion study. During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0025. The phase I study will enroll up to 154 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 28 days.

Read the detailed description

Dose escalation phase Approximately 19 to 74 subjects will receive escalating doses on HB0025 monotherapy. The escalating dose phase is composed of an accelerated titration design and a conventional 3+3 design.

During the dose escalation, when a given dose level completes the DLT observation period, an evaluation of PK, PD, biomarkers, tolerability and efficacy will be performed and if this dose level is considered as a possible candidate dose level for OBD. Determination of MTD or OBD will be expanded to a total of 6 subjects (if not already done due to observation of a DLT). After the MTD or OBD is determined, the dose group will continue to recruit subjects until the total number of subjects reaches 10 to confirm that the MTD or OBD is RP2D.

Dose escalation phase Approximately 80 subjects will be enrolled into expansion doses on HB0025. During the dose escalation process, dose expansion studies will be conducted based on the preliminary determination of RP2D and the expanded tumor types.

02

Conditions studied

  • Tumor, Subjects

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 154 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Huabo Biopharm Co., Ltd. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female. Age ≥ 18 years.
  2. Willing and able to provide signed and dated prior to any study-related procedures and willing and able to comply with all study procedures.
    1. Dose escalation phase: Patients with or cytologically confirmed advanced malignant solid tumor who have received or been intolerant of all standard therapies thought to confer clinical benefit. These solid tumors include but are not limited to hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal carcinoma (RCC), endometrial carcinoma, etc.
  1. Dose expansion phase:

a) Advanced HCC Cohort:

i) Unresectable HCC with diagnosis confirmed by histology/cytology or clinical criteria.

ii) Assessed by the investigator as likely to benefit from the study drug therapy; and should have progressed at least one prior systemic therapy regimen which could include but not limited to sorafenib, lenvatinib, donafenib, systematic chemotherapy,etc.

iii) Classification with score ≤ 6 points.(See Appendix13.6 for criteria) VI) test is negative.Patients with active hepatitis B virus (HBV) infection must have a viral load \< 500 IU/mL within 28 days prior to start of study treatment and be on suppressive therapy (per local standard of care) for a minimum of 14 days prior to start of study treatment and for the length of the study.

b) Advanced Renal Cell Carcinoma Cohort and Advanced Endometrial Carcinoma Cohort:

i) Histopathological and/or cytological diagnosis of patients with advanced clear cell renal carcinoma, advanced endometrial carcinoma, who are not suitable for radical treatment or have / disease; Advanced clear cell renal carcinoma should be assessed as medium-high risk by the International Metastatic Renal Cell Carcinoma Database Alliance (IMDC).

ii) Assessed by the investigator as likely to benefit from the study drug therapy Patient with disease progression from at least one previous systemic treatment or who are intolerant to the current standard treatment as determined by the investigator.

c) Other advanced solid tumor cohort: Patient with other advanced solid tumors that are not suitable for radical therapy or relapse /metastasis diagnosed histopathological and/or cytologically according to the type of tumor that responds well during the dose escalation phase.

  1. Accelerated escalation: Evaluable disease per v1.1 for solid tumors; Radiographic disease assessment at baseline can be performed up to 28 days prior to the first dose.
  1. 3+3 dose escalation and dose expansion cohort: At least one measurable tumor lesion as per RECIST criteria v1.1 defined as having at least one dimension with a minimum size of 10 mm in the longest diameter by CT or MRI scan for non-nodal lesions or ≥15 mm in short axis for nodal lesions. Radiographic disease assessment at baseline can be performed up to 28 days prior to the first dose.
  1. (ECOG) performance status 0-1.
  1. ≥3 months.
  1. Adequate hepatic function as evidenced by meeting all the following requirements:
  1. Total ≤ 1.5 × (ULN).
  2. and ALT ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present.
  1. Serum creatinine (Scr) \< 1.5 × ULN and calculated (CrCL) > 40 mL/min (Cockroft-Gault Equation).
  1. Hematological function defined as:
  1. ≥1,500/µL without growth factor support within 2 weeks prior to the first dose of HB0025.
  2. ≥ 9 g/dL without transfusion or erythropoietin within 2 weeks prior to the first dose of HB0025.
  3. count ≥ 75,000/µL without transfusion or recombinant human thrombopoietin within 2 weeks prior to the first dose of HB0025.
  1. Coagulation: (INR)≤1.6 (unless receiving anticoagulation therapy). Subjects on full-dose oral anticoagulation must be on a stable dose (minimum duration 14 days). If receiving warfarin, the subject must have an INR≤3.0 and no active bleeding (ie, no bleeding within 14 days prior to first dose of study drug). Subjects on low molecular weight heparin will be allowed. Subjects must have no active bleeding or bleeding within 14 days prior to first dose of study drug.
  1. Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy except alopecia, \< Grade 2 sensory neuropathy, lymphopenia, and endocrinopathies controlled with hormone replacement therapy.
  1. All patients will be required to provide (if available) archived paraffin blocks or at least 10 unstained slides prior to study entry. Patients who do not have available will be asked (optional) to provide fresh tissue from core-needle or punch biopsy.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria cannot be enrolled:

  1. Symptomatic central nervous system ; patients with asymptomatic who are radiologically and neurologically stable > 4 weeks following CNS-directed therapy, and are on a stable or decreasing dose of equivalent to \< 10 mg prednisone/day for at least 2 weeks prior to study treatment are eligible for study entry.
  2. Active disease or history of autoimmune disease requiring systemic therapy \< 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that has not been active in the 2 years prior to study screening are eligible.
  3. History of Grade 3-4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies, (except for grade 3 endocrinopathy that is managed with hormone replacement therapy).
  4. Use of systemic corticosteroids in a dose equivalent to > 10 mg/day of prednisone or other agent \< 2 weeks prior to screening; the use of topical, intraocular, intra-articular, intranasal or inhaled corticosteroids (systemic absorption is low) will be allowed to prevent (e.g., allergy to contrast agents) or treat non-autoimmune condition (e.g. delayed caused by exposure to allergens).
  5. Cerebrovascular accident (CVA), (TIA), myocardial infarction (MI), unstable angina, or (NYHA) class III or IV heart failure \< 6 months of study entry; mean -interval corrected according to Fridericia's formula (QTcF) > 470 milliseconds (ms) (males) or > 480 ms (females) obtained from three ECGs; uncontrolled arrhythmia \< 3 months of study entry. Patients with rate-controlled arrhythmias may be eligible for study entry at discretion of the Investigator.
  6. Uncontrolled diabetes mellitus with > 8%.
  7. Subjects who have received previous simultaneous therapy with a pathway inhibitor and a macromolecule VEGF inhibitor (Bevacizumab, Ramucirumab, etc).
  8. Anticancer therapy or radiation \< 5 half-lives or 4 weeks (whichever is shorter) prior to study entry; palliative radiotherapy to a single area \< 2 weeks prior to study screening is permitted. cannot be previously irradiated unless they have demonstrated growth after radiation therapy (RT).
  9. Prior stem cell, bone marrow or solid organ transplant.
  10. Concurrent \< 5 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, or \< T1 urothelial carcinoma. Patients with prostate cancer that is under active surveillance are eligible.
  11. Any of the following infections. 1) Active infection requiring intravenous therapy \< 2 weeks prior to screening. 2) Active tuberculosis (via medical history). 3) Positive test for antibody at screening. 4) Active or C. HBV carriers without active disease (HBV DNA titer \< 1000 cps/mL or 200 IU/mL), or cured (negative HCV RNA test) may be enrolled.
  12. Major surgery \< 4 weeks or minor surgery \< 2 weeks prior to screening; wound must be fully healed.
  13. History of severe allergic reactions, Grade 3-4 allergic reaction to treatment with another monoclonal antibody, or known to be allergic to protein drugs or recombinant proteins or in HB0025 drug formulation.
  14. \< 30 days prior to screening.
  15. Pregnant or breast-feeding females.
  16. Any agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment.
  17. Any other serious underlying medical condition (e.g. active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, cardiac conditions), or psychiatric, psychological, familial condition or geographical location that, in the judgment of the Investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
  18. Women of who do not consent to use acceptable methods of during treatment and for an additional 90 days after the last administration of HB0025.
  19. Men with a partner of childbearing potential who do not consent to use acceptable methods of birth control during treatment and for an additional 90 days after the last administration of HB0025.
  1. Single method i) Intrauterine device (IUD) ii) Vasectomy of a female subject's male partner iii) Contraceptive rod implanted into the skin 2) Combination method (requires use of two of the following) i) Diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide) ii) Cervical cap with spermicide (nulliparous women only) iii) Contraceptive sponge (nulliparous women only) iv) Male condom or female condom (cannot be used together) v) Hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or progestin -only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection.
  1. Positive COVID-19 qRT-PCR and/or serology test result during screening; 21. Subjects with a history of arterial or deep venous thrombosis within 3 months before enrollment, or patients with evidence or history of bleeding tendency within 2 months before enrollment, regardless of severity.
  1. Severe dyspnea or pulmonary dysfunction or need for continuous supportive oxygen inhalation.
  1. Skin wound, surgical site, wound site, mucosal ulcer, or fracture not completely healed; 24. Conditions that may cause gastrointestinal bleeding or perforation (such as duodenal ulcer, intestinal obstruction, Crohn's disease, ulcerative colitis, large-scale gastrectomy, etc.); patients with previous history of intestinal perforation and intestinal fistula but not cured after surgical treatment; esophageal and gastric varices.
  1. Subjects received immune modulators treatment, including but not limited to cyclosporine and tacrolimus, within 2 weeks before enrollment.
  1. Inability to comply with study and follow-up procedures. 27. Patients who have history of interstitial lung disease or non-infectious pneumonitis (except factor of radiation therapy; such patients should be discussed with the Medical Monitor before enrollment.
  1. Subjects who in the judgement of the Investigator are not suited to participate in this trial.
  1. Uncontrolled arterial hypertension despite standard treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).
  1. Patients with > 2+ protein on urine dipstick should have a 24-hour urine collection; Patients with ≥ 2 g of protein in the urine on 24-hour collection are ineligible for study entry.
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    HB0025

    HB0025 IV every 2 weeks (q2w)

    Drug: HB0025

Interventions

  • DrugHB0025

    Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.

    Also known as: Recombinant Humanized Anti-PD-L1 Monoclonal Antibody-VEGFR1 Fusion Protein

06

What researchers measure

Primary outcomes

  1. Safety assessment in dose-escalation phase

    Safety profile including adverse events, changes in safety assessment parameters (e.g. incidence of AEs, vital signs, ECGs, clinical laboratory results and DLTs);

    Time frame: 240 Days

  2. Safety assessment in dose-escalation phase

    MTD or OBD and/or RP2D.

    Time frame: 240 Days

  3. Efficacy assessment in dose-expansion phase

    ORR as measured by RECIST v1.1.

    Time frame: Up to 24 Moths

Secondary outcomes

  1. PK parameters in dose-escalation phase

    Area Under concentration-time Curve (AUC), Maximum serum concentration (Cmax), Clearance (CL), Volume of distribution (Vd), Mean Residence Time (MRT), half-life (t1/2), time of maximum concentration (Tmax), and average plasma concentration (Cavg).

    Time frame: 240 Days

  2. ORR assessment in dose-escalation phase

    Overall response rate (ORR) as measured by RECIST v1.1.

    Time frame: Up to 24 Months

  3. DCR assessment in dose-escalation phase

    Disease control rate (DCR) as measured by RECIST v1.1.

    Time frame: Up to 24 Months

  4. DOR assessment in dose-escalation phase

    Duration of response (DOR) as measured by RECIST v1.1.

    Time frame: Up to 24 Months

  5. PFS assessment in dose-escalation phase

    Progression-free survival (PFS) as measured by RECIST v1.1.

    Time frame: Up to 24 Months

  6. ADA assessment in dose-escalation phase

    Anti-drug antibody (ADA) and neutralizing antibodies (Nab).

    Time frame: Up to 24 Months

  7. DOR assessment in dose-expansion phase

    Duration of response (DOR) as evaluated by investigators according to RECIST v1.1

    Time frame: Up to 24 Months

  8. PFS assessment in dose-expansion phase

    Progression-free survival (PFS) as evaluated by investigators according to RECIST v1.1

    Time frame: Up to 24 Months

  9. OS rate(12M) assessment in dose-expansion phase

    The 12-month OS rate (OS12m) as evaluated by investigators according to RECIST v1.1

    Time frame: 12 Months

  10. OS assessment in dose-expansion phase

    Overall survival (OS) as evaluated by investigators according to RECIST v1.1

    Time frame: Up to 24 Months

  11. ADA assessment in dose-expansion phase

    Anti-drug antibody (ADA) and neutralizing antibodies (Nab).

    Time frame: 240 Days

  12. PK parameters in dose-expansion phase

    Area Under concentration-time Curve (AUC), Maximum serum concentration (Cmax), Clearance (CL), Volume of distribution (Vd), Mean Residence Time (MRT), half-life (t1/2)、time to maximum concentration (Tmax)、and average plasma concentration (Cavg).

    Time frame: 240 Days

07

Study locations

6 of 6 sites recruiting
  • NEXT Oncology
    San Antonio, Texas 78229, United States
    Recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
    Recruiting
  • Central Hospital Affiliated to ShanDong First Medical University
    Jinan, Shandong 250000, China
    Recruiting
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
    Recruiting
  • Linyi Cancer Hospital
    Linyi, Shandong 726000, China
    Recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 201210, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Feb 2024, 34 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 34 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Dec 22, 2020
StartActual
Mar 10, 2021
Primary completionEst.
Feb 2, 2024
CompletionEst.
May 23, 2024
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04678908
Lead sponsor
Huabo Biopharm Co., Ltd.
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Mar 10, 2021
Primary completion
Feb 2, 2024 (estimated)
Completion
May 23, 2024 (estimated)
Last update
Jun 1, 2022

Study contacts

Anthony Tolcher
Contact
atolcher@nextoncology.com
210-580-9500

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotiburafusp alfa

Start the discussion